Target Development towards First Production of High-Molar- Activity 44gSc and 47Sc by Mass Separation at CERN-MEDICIS
Pharmaceuticals · 18.03.2024 · 17 (3) · 390
DOI: 10.3390/ph17030390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 18.03.2024. Verfasst von Edgars Mamis und 21 weiteren Autor:innen. Beteiligte Einrichtung: European Organization for Nuclear Research (CERN), Esplanade des Particules 1, 1211 Geneva, Switzerland. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Latvian Council of Science, the European Union's Horizon 2020 research and innovation programme, European Union’s Horizon 2020.
Abstract (Originalsprache)
The radionuclides 43Sc, 44g/mSc, and 47Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47Sc in the highest cross section energy range of 24–70 MeV results in the co-production of long-lived, high-γ-ray-energy 46Sc and 48Sc contaminants if one does not use enriched target materials. Mass separation can be used to obtain high molar activity and isotopically pure Sc radionuclides from natural target materials; however, suitable operational conditions to obtain relevant activity released from irradiated natTi and natV have not yet been established at CERN-MEDICIS and ISOLDE. The objective of this work was to develop target units for the production, release, and purification of Sc radionuclides by mass separation as well as to investigate target materials for the mass separation that are compatible with high-yield Sc radionuclide production in the 9–70 MeV proton energy range. In this study, the in-target production yield obtained at MEDICIS with 1.4 GeV protons is compared with the production yield that can be reached with commercially available cyclotrons. The thick-target materials were irradiated at MEDICIS and comprised of metallic natTi, natV metallic foils, and natTiC pellets. The produced radionuclides were subsequently released, ionized, and extracted from various target and ion source units and mass separated. Mono-atomic Sc laser and molecule ionization with forced-electron-beam-induced arc-discharge ion sources were investigated. Sc radionuclide production in thick natTi and natV targets at MEDICIS is equivalent to low- to medium-energy cyclotron-irradiated targets at medically relevant yields, furthermore benefiting from the mass separation possibility. A two-step laser resonance ionization scheme was used to obtain mono-atomic Sc ion beams. Sc radionuclide release from irradiated target units most effectively could be promoted by volatile scandium fluoride formation. Thus, isotopically pure 44g/mSc, 46Sc, and 47Sc were obtained as mono-atomic and molecular ScF 2+ ion beams and collected for the first time at CERN-MEDICIS. Among all the investigated target materials, natTiC is the most suitable target material for Sc mass separation as molecular halide beams, due to high possible operating temperatures and sustained release.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- European Organization for Nuclear Research (CERN), Esplanade des Particules 1, 1211 Geneva, Switzerland.
- Institute of Chemical Physics (ICP), University of Latvia, Jelgavas Street 1, LV-1004 Riga, Latvia.
- Institut für Physik, Johannes Gutenberg Universität, Staudingerweg 7, 55128 Mainz, Germany.
- Instituto Superior de Tecnologías y Ciencias Aplicadas, Universidad de La Habana (InSTEC-UH), Ave. Salvador Allende No. 1110 e, Infanta y Rancho Boyeros, Plaza de la Revolucion, La Habana 10400, Cuba.
- Department of Physics and Astronomy (IKS), Katholieke Universiteit Leuven, Celestijnenlaan 200D, 3010 Heverlee, Belgium.
ORCID-Profile: Edgars Mamis, Charlotte Duchemin, Valentina Berlin, Cyril Bernerd, Reinhard Heinke, Ronaldo Mendez Hernandez, Jake David Johnson, Patrīcija Kalniņa, Laura Lambert, Felix Weber, Rudolfs Jānis Zabolockis, Elīna Pajuste, Thierry Stora
Förderung
- Latvian Council of Science
- the European Union's Horizon 2020 research and innovation programme
- European Union’s Horizon 2020
Zitieren
APA
Mamis, E., Duchemin, C., Berlin, V., Bernerd, C., Bovigny, M., Chevallay, E., Crepieux, B., Gadelshin, V. M., Heinke, R., Hernandez, R. M., Johnson, J. D., Kalniņa, P., Koliatos, A., Lambert, L., Rossel, R. E., Rothe, S., Thiboud, J., Weber, F., Wendt, K., …, & Stora, T. (2024). Target Development towards First Production of High-Molar- Activity 44gSc and 47Sc by Mass Separation at CERN-MEDICIS. Pharmaceuticals, 17(3), 390. https://doi.org/10.3390/ph17030390
Vancouver
Mamis E, Duchemin C, Berlin V, Bernerd C, Bovigny M, Chevallay E, et al. Target Development towards First Production of High-Molar- Activity 44gSc and 47Sc by Mass Separation at CERN-MEDICIS. Pharmaceuticals. 2024;17(3):390. doi:10.3390/ph17030390
BibTeX
@article{Mamis2024,
author = {Mamis, Edgars and Duchemin, Charlotte and Berlin, Valentina and Bernerd, Cyril and Bovigny, Mathieu and Chevallay, Eric and Crepieux, Bernard and Gadelshin, Vadim Maratovich and Heinke, Reinhard and Hernandez, Ronaldo Mendez and Johnson, Jake David and Kalniņa, Patrīcija and Koliatos, Alexandros and Lambert, Laura and Rossel, Ralf Erik and Rothe, Sebastian and Thiboud, Julien and Weber, Felix and Wendt, Klaus and Zabolockis, Rudolfs Jānis and Pajuste, Elīna and Stora, Thierry},
title = {Target Development towards First Production of High-Molar- Activity 44gSc and 47Sc by Mass Separation at CERN-MEDICIS},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {3},
pages = {390},
doi = {10.3390/ph17030390}
}
EUVIMED